Show simple item record

dc.contributor.authorSpinthakis, Nikolaos
dc.contributor.authorFarag, Mohamed
dc.contributor.authorRocca, Bianca
dc.contributor.authorGorog, Diana
dc.date.accessioned2019-04-23T14:05:46Z
dc.date.available2019-04-23T14:05:46Z
dc.date.issued2018-02-06
dc.identifier.citationSpinthakis , N , Farag , M , Rocca , B & Gorog , D 2018 , ' More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. ' , Journal of the American Heart Association , vol. 7 , no. 3 , pp. 1-10 . https://doi.org/10.1161/JAHA.117.007754
dc.identifier.issn2047-9980
dc.identifier.otherPURE: 16605410
dc.identifier.otherPURE UUID: 476b9320-ba05-4d21-b9cc-32f3927bbf9d
dc.identifier.otherScopus: 85041659387
dc.identifier.urihttp://hdl.handle.net/2299/21294
dc.description© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
dc.description.abstractCommon to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the coagulation cascade.1 To attenuate the risk of future thrombotic events, patients with ACS are treated with dual antiplatelet therapy (DAPT), namely, the combination of aspirin with a P2Y12 inhibitor, such as clopidogrel, ticagrelor, or prasugrel. Despite DAPT, some ≈10% of ACS patients experience recurrent major adverse cardiovascular events over the subsequent 30 days,2 driving the quest for more effective inhibition of thrombotic pathways. In this review, we provide an overview of studies to date and those ongoing that aim to deliver more effective combinations of antithrombotic agents to patients with recent ACS. We have chosen to confine the review to ACS patients without atrial fibrillation because those with atrial fibrillation have a clear indication for combination therapy that includes oral anticoagulation and should, we feel, be treated as a separate cohort. In this article, we discuss the limitations of the currently available clinical trial data and future directions, with suggestions for how practice might change to reduce the risk of coronary thrombosis in those at greatest risk, with minimal impact on bleeding.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofJournal of the American Heart Association
dc.rightsOpen
dc.titleMore, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions.en
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dc.description.versiontypeFinal Published version
dcterms.dateAccepted2018-02-06
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1161/JAHA.117.007754
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeOpen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record